Fintel reports that on November 4, 2024, Jefferies upgraded their outlook for Vertex (NasdaqGM:VERX) from Hold to Buy.

Vertex Background Information (This description is provided by the company.) Vertex, Inc. is a leading global provider of indirect tax software and solutions. The company’s mission is to deliver ...

Following a sanctions hearing pursuant to the Mutual Fund Dealer Rules held on August 30 and September 5, 2024, a hearing panel of the Canadian Investment Regulatory Organization (CIRO) imposed the ...

This article reviews promising technologies leveraging AI to improve everyday experiences through chatbots, accessibility ...

The most famous one would be the Cystic Fibrosis Foundation, which supported and developed the cystic fibrosis drug Trikafta [with] Vertex Pharmaceuticals ... we [went to] a family office that has a ...

Vertex (VERX – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Chris Quintero from ...

Vertex, Inc. ( (VERX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex, Inc. presented to its investors. Vertex, ...

Good day and welcome to the Vertex Inc third quarter, 2024 earnings conference call. All participants will be in listen-only mode. Should you need assistance? Please signal a conference specialist ...

As Vertex Pharmaceuticals Inc. heads toward the end of 2024, the Boston drugmaker is gearing up for two potential drug ...

Good day and welcome to the Vertex Inc third quarter, 2024 earnings conference call. All participants will be in listen-only mode. Should you need assistance? Please signal a conference specialist by ...

Unrestricted Cash and Cash Equivalents: Over $279 million. Vertex Inc (NASDAQ:VERX) reported strong financial results with a revenue of $170.4 million, marking a 17.5% year-over-year growth.